LTβR (E5I6X) Rabbit mAb (Alexa Fluor® 488 Conjugate) #81130
- F
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | |
| Source/Isotype | Rabbit IgG |
Application Key:
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Description
Product Usage Information
| Application | Dilution |
|---|---|
| Flow Cytometry (Fixed/Permeabilized) | 1:50 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg428 of human LTβR protein.
Background
Lymphotoxin β receptor (LTβR), also known as tumor necrosis factor receptor superfamily member 3 (TNFRSF3) and tumor necrosis factor receptor type III (TNF-RIII), is a type I membrane receptor expressed by stromal cells, including endothelial, mesenchymal, and epithelial cells, and by myeloid cells, such as dendritic cells and macrophages (1-4). When lymphotoxin α (LTα) is co-expressed with lymphotoxin β (LTβ) that possesses a transmembrane domain, it forms a cell surface-bound heterotrimer (LTα1β2) that exclusively binds to LTβR (5,6). The LTα1β2/LTβR pathway is required for the normal development of lymph nodes and Peyer’s patches (7,8). Disruption of the LTα1β2/LTβR pathway results in impaired protection from viral and bacterial infections (9,10). LTβR is also a receptor for LIGHT/TNFSF14 (11,12). LTβR signaling through LIGHT/TNFSF14 regulates self-renewal and differentiation of hematopoietic and leukemic stem cells (13). In cancer cells, LTβR signaling via TRAF molecules promotes apoptosis (14-16). Agonistic antibodies to LTβR trigger cancer cell death and suppress tumor growth in vivo (17).
- Murphy, M. et al. (1998) Cell Death Differ 5, 497-505.
- Browning, J.L. and French, L.E. (2002) J Immunol 168, 5079-87.
- Browning, J.L. et al. (1997) J Immunol 159, 3288-98.
- Kabashima, K. et al. (2005) Immunity 22, 439-50.
- Androlewicz, M.J. et al. (1992) J Biol Chem 267, 2542-7.
- Browning, J.L. et al. (1993) Cell 72, 847-56.
- De Togni, P. et al. (1994) Science 264, 703-7.
- Fütterer, A. et al. (1998) Immunity 9, 59-70.
- Ehlers, S. et al. (2003) J Immunol 170, 5210-8.
- Wege, A.K. et al. (2014) Innate Immun 20, 461-70.
- Maeda, T. et al. (2018) J Immunol 201, 202-214.
- Schneider, K. et al. (2004) Immunol Rev 202, 49-66.
- Höpner, S.S. et al. (2021) Nat Commun 12, 1065.
- Browning, J.L. et al. (1996) J Exp Med 183, 867-78.
- Force, W.R. et al. (1997) J Biol Chem 272, 30835-40.
- Rooney, I.A. et al. (2000) J Biol Chem 275, 14307-15.
- Lukashev, M. et al. (2006) Cancer Res 66, 9617-24.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专